MTOR and prostate carcinoma: Moreover, cancer-associated fibroblasts present in the reactive tumoral stroma can activate MAO-A in prostate cancer cells with consequent ROS overproduction and mTOR/HIF1α signaling that leads to EMT and the increased expression of the CXCR4 and IL-6 receptor, promoting a migratory and aggressive prostate tumor phenotype [58].